168 related articles for article (PubMed ID: 35216305)
21. Molecular differential analysis of uterine leiomyomas and leiomyosarcomas through weighted gene network and pathway tracing approaches.
Sahly NN; Banaganapalli B; Sahly AN; Aligiraigri AH; Nasser KK; Shinawi T; Mohammed A; Alamri AS; Bondagji N; Elango R; Shaik NA
Syst Biol Reprod Med; 2021 Jun; 67(3):209-220. PubMed ID: 33685300
[TBL] [Abstract][Full Text] [Related]
22. Immunoexpression of progesterone receptor, epithelial growth factor receptor and galectin-3 in uterine smooth muscle tumors.
Soltan MM; Albasry AM; Eldosouky MK; Abdelhamid HS
Cell Mol Biol (Noisy-le-grand); 2018 Apr; 64(5):7-12. PubMed ID: 29729689
[TBL] [Abstract][Full Text] [Related]
23. [Expression of bcl-2 and bax protein in uterine leiomyosarcomas and leiomyomas].
Zhang ZL; Zhang Y; Zhou JH
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Apr; 30(2):183-6. PubMed ID: 15898430
[TBL] [Abstract][Full Text] [Related]
24. Expression of the mitogen-inducible gene-2 (mig-2) is elevated in human uterine leiomyomas but not in leiomyosarcomas.
Kato K; Shiozawa T; Mitsushita J; Toda A; Horiuchi A; Nikaido T; Fujii S; Konishi I
Hum Pathol; 2004 Jan; 35(1):55-60. PubMed ID: 14745725
[TBL] [Abstract][Full Text] [Related]
25. Cell cycle regulatory markers in uterine atypical leiomyoma and leiomyosarcoma: immunohistochemical study of 68 cases with clinical follow-up.
Mills AM; Ly A; Balzer BL; Hendrickson MR; Kempson RL; McKenney JK; Longacre TA
Am J Surg Pathol; 2013 May; 37(5):634-42. PubMed ID: 23552380
[TBL] [Abstract][Full Text] [Related]
26. The Usefulness of Immunohistochemistry in the Differential Diagnosis of Lesions Originating from the Myometrium.
Rubisz P; Ciebiera M; Hirnle L; Zgliczyńska M; Łoziński T; Dzięgiel P; Kobierzycki C
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30845657
[TBL] [Abstract][Full Text] [Related]
27. P16, Ki67, P53, and WT1 Expression in Uterine Smooth Muscle Tumors: An Adjunct in Confirming the Diagnosis of Malignancy in Ambiguous Cases.
Delgado B; Dreiher J; Braiman D; Meirovitz M; Shaco-Levy R
Int J Gynecol Pathol; 2021 May; 40(3):257-262. PubMed ID: 32897968
[TBL] [Abstract][Full Text] [Related]
28. Analysis of allelic loss as an adjuvant tool in evaluation of malignancy in uterine smooth muscle tumors.
Esposito NN; Hunt JL; Bakker A; Jones MW
Am J Surg Pathol; 2006 Jan; 30(1):97-103. PubMed ID: 16330948
[TBL] [Abstract][Full Text] [Related]
29. Frequent loss of heterozygosity for chromosome 10 in uterine leiomyosarcoma in contrast to leiomyoma.
Quade BJ; Pinto AP; Howard DR; Peters WA; Crum CP
Am J Pathol; 1999 Mar; 154(3):945-50. PubMed ID: 10079273
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical expression of CD44 standard and E-cadherin in atypical leiomyoma and leiomyosarcoma of the uterus.
Kaygusuz EI
J Obstet Gynaecol; 2015 Apr; 35(3):279-82. PubMed ID: 25140670
[TBL] [Abstract][Full Text] [Related]
31. p53 alterations in uterine leiomyosarcomas versus leiomyomas.
de Vos S; Wilczynski SP; Fleischhacker M; Koeffler P
Gynecol Oncol; 1994 Aug; 54(2):205-8. PubMed ID: 8063247
[TBL] [Abstract][Full Text] [Related]
32. Oncofetal protein IMP3: a useful diagnostic biomarker for leiomyosarcoma.
Cornejo K; Shi M; Jiang Z
Hum Pathol; 2012 Oct; 43(10):1567-72. PubMed ID: 22497850
[TBL] [Abstract][Full Text] [Related]
33. Immunoexpression of p53 in cutaneous and subcutaneous leiomyosarcomas.
Fernandez-Flores A; Monteagudo C
Ann Diagn Pathol; 2016 Oct; 24():25-9. PubMed ID: 27649950
[TBL] [Abstract][Full Text] [Related]
34. Chromosome aberrations in uterine smooth muscle tumors: potential diagnostic relevance of cytogenetic instability.
Fletcher JA; Morton CC; Pavelka K; Lage JM
Cancer Res; 1990 Jul; 50(13):4092-7. PubMed ID: 2354458
[TBL] [Abstract][Full Text] [Related]
35. MED12 exon 2 mutations in uterine and extrauterine smooth muscle tumors.
Schwetye KE; Pfeifer JD; Duncavage EJ
Hum Pathol; 2014 Jan; 45(1):65-70. PubMed ID: 24196187
[TBL] [Abstract][Full Text] [Related]
36. Potential role of preoperative serum CA125 for the differential diagnosis between uterine leiomyoma and uterine leiomyosarcoma.
Juang CM; Yen MS; Horng HC; Twu NF; Yu HC; Hsu WL
Eur J Gynaecol Oncol; 2006; 27(4):370-4. PubMed ID: 17009628
[TBL] [Abstract][Full Text] [Related]
37. Integrated histologic and molecular analysis of uterine leiomyosarcoma and 2 benign variants with nuclear atypia.
Gao T; Finkelman BS; Ban Y; Li Y; Yin P; Bulun SE; Lu X; Ha C; Wei JJ
Cancer Sci; 2021 May; 112(5):2046-2059. PubMed ID: 33338329
[TBL] [Abstract][Full Text] [Related]
38. Potential Markers to Differentiate Uterine Leiomyosarcomas from Leiomyomas.
Guo J; Zheng J; Tong J
Int J Med Sci; 2024; 21(7):1227-1240. PubMed ID: 38818470
[TBL] [Abstract][Full Text] [Related]
39. Analysis of Ki-ras, p53, and MDM2 genes in uterine leiomyomas and leiomyosarcomas.
Hall KL; Teneriello MG; Taylor RR; Lemon S; Ebina M; Linnoila RI; Norris JH; Park RC; Birrer MJ
Gynecol Oncol; 1997 May; 65(2):330-5. PubMed ID: 9159347
[TBL] [Abstract][Full Text] [Related]
40. T2 hyperintense myometrial tumors: can MRI features differentiate leiomyomas from leiomyosarcomas?
Rio G; Lima M; Gil R; Horta M; Cunha TM
Abdom Radiol (NY); 2019 Oct; 44(10):3388-3397. PubMed ID: 31250178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
